Navigation Links
Royalty Pharma Announces Marshall Urist, MD, PhD, Joins Management Team
Date:7/19/2013

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. 

Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research Team. 

"We are excited to have Marshall join our team. He has had a distinguished career on Wall Street, and this experience coupled with his deep analytical skills make him an excellent addition to Royalty Pharma," said Pablo Legorreta, Founder and CEO of Royalty Pharma.

Dr. Urist graduated Phi Beta Kappa from Johns Hopkins University and holds a MD and PhD from Columbia University.

About Royalty Pharma

Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products. With over $10 billion in assets, Royalty Pharma owns royalty interests in 41 marketed and late stage biopharmaceutical products, including Abbott's Humira®, Johnson and Johnson's Remicade® and Prezista®, Gilead's Atripla®, Truvada®, Complera® and Emtriva®, Pfizer's Lyrica®, Amgen's Neupogen® and Neulasta®, Genentech's Rituxan®, Astella's Lexiscan®, Merck's Januvia/Janumet®, Roche's Mircera®, UCB's Cimzia®, Biogen Idec's Tecifidera® and Pharmacyclics' ibrutinib. Additional company information is available at royaltypharma.com.

Royalty Pharma | RP Management LLC
Investor Relations
+
'/>"/>

SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Cowen Healthcare Royalty Partners Raises $1 Billion
2. PDL BioPharma Provides Third Quarter 2012 Royalty Revenue Guidance of $85 Million
3. Royalty Pharma Statement Regarding Elan Proposal
4. Cadwalader Advises Elan Corporation in Billion Dollar Royalty Deal
5. Royalty Pharma Statement Regarding Elan Law Suits
6. Royalty Pharma Increases Offer to Acquire Elan to $13.00 Per Share in Cash Plus a Contingent Value Right of Up to $2.50 Per Share
7. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. WuXi PharmaTech Announces Third-Quarter 2011 Results
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Pharmasset Reports Fiscal Year End 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... A n ... rapidly developing and commercialising innovative medicines to transform patient quality ... Highly experienced management team; blue chip ... Mereo BioPharma Group Ltd ("Mereo"), a recently-formed speciality biopharmaceutical company, ... £76.5m), gross, from blue chip institutional investors and simultaneously acquired ...
(Date:7/28/2015)... , ... July 29, 2015 , ... The new Xsample 530 sample changer for ... a wide range of liquid viscosities – from less than 12,000 mPas (internal air) up ... vials. , What immediately catches the eye about Xsample 530 is its removable magazine, ...
(Date:7/28/2015)... NEW YORK , July 28, 2015 ... helped by hearing aids achieved significant and sometimes profound ... hybrid cochlear implant devices, according to a new multicenter ... In the study, described online ahead of ... 10 medical centers and private clinics in ...
(Date:7/28/2015)... ... July 28, 2015 , ... In terms of ... 2013; while production volume reached close to 1.84 million tonnes in the same ... of 75.5% of the region’s total aluminium hydroxide production; the country’s aluminium hydroxide ...
Breaking Biology Technology:Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11New Moves in Automatic Sample Handling: Introducing Xsample 530 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 2EU27 Aluminium Hydroxide Market Analysed and Forecast by BAC Reports in New Research Study Available at MarketPublishers.com 3
... DIEGO, May 1, 2012 AnaptysBio, Inc., a ... discovery partnership with Gilead Sciences, Inc. to develop ... http://photos.prnewswire.com/prnh/20111205/SF16052LOGO ) Under this partnership, ... platform will be transferred to Gilead for worldwide ...
... research project, funded by the British Heart Foundation (BHF), has ... doctors predict a patient,s risk of having a heart attack ... BHF Centre of Research Excellence, in collaboration with the University ... combining PET and CT scanning to image the disease processes ...
... age of high-speed computing, the photon is king. However, producing ... time-consuming process, until now. Thanks to the work by ... The Edward S. Rogers Sr. Department of Electrical & Computer ... the production of special class of photons faster and easier. ...
Cached Biology Technology:AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences 2 Scientists develop new technique that could improve heart attack prediction 2Research breakthrough takes supercomputing out of the lab 2
(Date:6/30/2015)... 30, 2015 Genisphere announced ... to help further develop Genisphere,s therapeutics capabilities and portfolio. ... having spent much of the last 25 years in ... Bioscience, and Johnson & Johnson. Tom started his career ... Biotech Corporate Finance. He graduated from Dartmouth College with ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... June 24, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Sharp has selected its ... authentication for its latest flagship smartphone device, the ... 200 million shipments of its fingerprint ID sensor ... strength, scalability and leadership in the biometrics market ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
... high tech tools, researchers have identified three proteins that ... 20 months before the rejection occurred. , Lung transplant ... about 45% over five years, said lead investigator and ... to predict which transplants will fail, and when signs ...
... for the survival of many types of cells stimulates ... that connect the cerebral cortex with the spinal cord ... lateral sclerosis (ALS or Lou Gehrig's disease). In ... from Massachusetts General Hospital (MGH) and the Harvard Stem ...
... during the earliest phases of infection appears to depend ... called HLA Class I that have been inherited, as ... molecules display to the T lymphocytes that usually destroy ... issue of PLOS Medicine, researchers from the Partners AIDS ...
Cached Biology News:Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3Growth factor stimulates rapid extension of key motor neurons in brain 2Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
... is a hydrolytic enzyme that catalyzes ... of glucose, maltose, maltotriose and,dextrins. The ... of the human,body are of clinical ... important enzymes for industry.4, The EnzChek ...
... new Class II safety cabinets Heraeus HERAsafe KS ... user-orientated design. ,The new frameless slanted window ... area. The new front window design makes it ... large work aperture with a height of more ...
Biology Products: